MRX Stock Analysis: Marex Ordinary Shares | NASDAQ
Capital Markets | NASDAQ, USA | Market Cap: 4.504m USD | 12M Return: 75.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 54.3M
Qual. Beats: 2
Rev. Trend: 88.7%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 2.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Marex Group plc is a London-based financial services platform company listed on NASDAQ under the ticker MRX, providing liquidity, market access, and infrastructure services across commodity and financial markets in the UK, US, and internationally. Founded in 2005 and IPOd in 2024, the company operates through four segments: Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions.
Its service offerings span execution and clearing across metals, agricultural products, energy, fixed income, financial securities, digital assets, and equity futures and options. Marex also provides liquidity in OTC energy markets, market data and analytics, energy market services, and OTC hedging and derivatives solutions. The structured notes business enables investors to build products across commodities, equities, FX, and fixed income for distribution to private banks, asset managers, pension funds, and corporates.
The company supports its operations with proprietary technology platforms, including Neon (a trading, risk, and data platform) and Agile (a commodity broking platform). As a mid-cap financial services firm, Marex sits within the investment banking and brokerage sub-industry, a sector that benefits from increased market volatility and client demand for hedging and execution services.
- Commodity volatility drives Market Making and Execution revenue
- Structured notes growth lifts Hedging and Investment Solutions margins
- Fed rate cuts pressure net interest margins on client balances
| Net Income: 493.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.90 > 1.0 |
| NWC/Revenue: 48.59% < 20% (prev 48.32%; Δ 0.27% < -1%) |
| CFO/TA 0.02 > 3% & CFO 667.5m > Net Income 493.8m |
| Net Debt (7.26b) to EBITDA (1.66b): 4.38 < 3 |
| Current Ratio: 1.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.9m) vs 12m ago -8.72% < -2% |
| Gross Margin: 62.27% > 18% (prev 42.34%; Δ 19.94% > 0.5%) |
| Asset Turnover: 17.90% > 50% (prev 17.05%; Δ 0.85% > 0%) |
| Interest Coverage Ratio: 2.13 > 6 (EBIT TTM 1.62b / Interest Expense TTM 760.2m) |
| A: 0.07 (Total Current Assets 35.4b - Total Current Liabilities 32.8b) / Total Assets 36.5b |
| B: 0.03 (Retained Earnings 1.08b / Total Assets 36.5b) |
| C: 0.05 (EBIT TTM 1.62b / Avg Total Assets 30.4b) |
| D: 0.04 (Book Value of Equity 1.35b / Total Liabilities 35.2b) |
| Altman-Z'' = 0.97 = BB |
| DSRI: 0.84 (Receivables 10.7b/9.75b, Revenue 5.45b/4.15b) |
| GMI: 0.68 (GM 42.34% / 62.27%) |
| AQI: 1.35 (AQ_t 0.03 / AQ_t-1 0.02) |
| SGI: 1.31 (Revenue 5.45b / 4.15b) |
| TATA: -0.00 (NI 493.8m - CFO 667.5m) / TA 36.5b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 28, 2026, the stock is trading at USD 64.60 with a total of 645,046 shares traded. Over the past week, the price has changed by +3.16%, over one month by +9.60%, over three months by +21.96% and over the past year by +75.46%.
Current recommended Stop Loss: 56.50 (which is 12.5% or 2.6 ATR below the current price).
Marex Ordinary Shares has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy MRX.
- StrongBuy: 3
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 72.4 | 12% |
P/E Trailing = 14.9049
P/E Forward = 8.7642
P/S = 1.2262
P/B = 3.5118
Revenue TTM = 5.45b USD
EBIT TTM = 1.62b USD
EBITDA TTM = 1.66b USD
Long Term Debt = 2.28b USD (from longTermDebt, last quarter)
Short Term Debt = 7.99b USD (from shortLongTermDebt, last quarter)
Debt = 10.3b USD (from shortLongTermDebtTotal, last fiscal year) + Leases 94.8m
Net Debt = 7.26b USD (calculated: Debt 10.3b - CCE 3.07b)
Enterprise Value = 11.8b USD (4.50b + Debt 10.3b - CCE 3.07b)
Interest Coverage Ratio = 2.13 (Ebit TTM 1.62b / Interest Expense TTM 760.2m)
EV/FCF = 17.98x (Enterprise Value 11.8b / FCF TTM 654.4m)
FCF Yield = 5.56% (FCF TTM 654.4m / Enterprise Value 11.8b)
FCF Margin = 12.01% (FCF TTM 654.4m / Revenue TTM 5.45b)
Net Margin = 9.06% (Net Income TTM 493.8m / Revenue TTM 5.45b)
Gross Margin = 62.27% ((Revenue TTM 5.45b - Cost of Revenue TTM 2.06b) / Revenue TTM)
Gross Margin QoQ = 36.59% (prev 80.45%)
Tobins Q-Ratio = 0.32 (Enterprise Value 11.8b / Total Assets 36.5b)
Interest Expense / Debt = 7.36% (Interest Expense 760.2m / Debt 10.3b)
Taxrate = 17.52% (115.7m / 660.2m)
NOPAT = 1.33b (EBIT 1.62b * (1 - 17.52%))
Current Ratio = 1.08 (Total Current Assets 35.4b / Total Current Liabilities 32.8b)
Debt / Equity = 7.66 (Debt 10.3b / totalStockholderEquity, last quarter 1.35b)
Debt / EBITDA = 4.38 (Net Debt 7.26b / EBITDA 1.66b)
Debt / FCF = 11.10 (Net Debt 7.26b / FCF TTM 654.4m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.62% (Net Income 493.8m / Total Assets 36.5b)
RoE = 40.28% (Net Income TTM 493.8m / Total Stockholder Equity 1.23b)
RoCE = 46.16% (EBIT 1.62b / Capital Employed (Equity 1.23b + L.T.Debt 2.28b))
RoIC = 11.81% (NOPAT 1.33b / Invested Capital 11.3b)
WACC = 7.08% (E(4.50b)/V(14.8b) * Re(9.41%) + D(10.3b)/V(14.8b) * Rd(7.36%) * (1-Tc(0.18)))
Discount Rate = 9.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 10.21 | Cagr: 0.70%
[DCF] Terminal Value 73.10% ; FCFF base≈850.1m ; Y1≈745.5m ; Y5≈602.3m
[DCF] Fair Price = 33.46 (EV 9.67b - Net Debt 7.26b = Equity 2.41b / Shares 71.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 2
Revenue Correlation: 88.70 | Revenue CAGR: 31.96% | SUE: 0.91 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.36 | Chg30d=+9.43% | Revisions=+25% | Analysts=7
EPS next Quarter (2026-09-30): EPS=1.24 | Chg30d=+1.72% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=5.20 | Chg30d=-0.33% | Revisions=+40% | GrowthEPS=+30.2% | GrowthRev=+24.5%
EPS next Year (2027-12-31): EPS=5.82 | Chg30d=+4.54% | Revisions=+40% | GrowthEPS=+12.0% | GrowthRev=+3.9%
[Analyst] Revisions Ratio: +50% (up=6, down=1)